Logo image of MRX.DE

MISTER SPEX SE (MRX.DE) Stock Fundamental Analysis

FRA:MRX - DE000A3CSAE2 - Common Stock

1.69 EUR
-0.15 (-8.15%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

2

Overall MRX gets a fundamental rating of 2 out of 10. We evaluated MRX against 47 industry peers in the Specialty Retail industry. MRX may be in some trouble as it scores bad on both profitability and health. MRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MRX had negative earnings in the past year.
MRX had a negative operating cash flow in the past year.
In the past 5 years MRX always reported negative net income.
In the past 5 years MRX reported 4 times negative operating cash flow.
MRX.DE Yearly Net Income VS EBIT VS OCF VS FCFMRX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of MRX (-50.10%) is worse than 90.20% of its industry peers.
MRX has a worse Return On Equity (-125.35%) than 90.20% of its industry peers.
Industry RankSector Rank
ROA -50.1%
ROE -125.35%
ROIC N/A
ROA(3y)-27.31%
ROA(5y)-20%
ROE(3y)-57.09%
ROE(5y)-43%
ROIC(3y)N/A
ROIC(5y)N/A
MRX.DE Yearly ROA, ROE, ROICMRX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

MRX has a Gross Margin of 51.82%. This is amongst the best in the industry. MRX outperforms 80.39% of its industry peers.
In the last couple of years the Gross Margin of MRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for MRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y0.94%
MRX.DE Yearly Profit, Operating, Gross MarginsMRX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

3

2. Health

2.1 Basic Checks

MRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MRX has been increased compared to 5 years ago.
The debt/assets ratio for MRX is higher compared to a year ago.
MRX.DE Yearly Shares OutstandingMRX.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
MRX.DE Yearly Total Debt VS Total AssetsMRX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MRX has an Altman-Z score of -2.11. This is a bad value and indicates that MRX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.11, MRX is doing worse than 78.43% of the companies in the same industry.
MRX has a Debt/Equity ratio of 0.79. This is a neutral value indicating MRX is somewhat dependend on debt financing.
MRX has a worse Debt to Equity ratio (0.79) than 62.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z -2.11
ROIC/WACCN/A
WACC5.14%
MRX.DE Yearly LT Debt VS Equity VS FCFMRX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 2.47 indicates that MRX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 2.47, MRX belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
MRX has a Quick Ratio of 1.82. This is a normal value and indicates that MRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.82, MRX belongs to the top of the industry, outperforming 92.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 1.82
MRX.DE Yearly Current Assets VS Current LiabilitesMRX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for MRX have decreased strongly by -66.36% in the last year.
Looking at the last year, MRX shows a decrease in Revenue. The Revenue has decreased by -6.33% in the last year.
MRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.25% yearly.
EPS 1Y (TTM)-66.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.59%
Revenue 1Y (TTM)-6.33%
Revenue growth 3Y3.73%
Revenue growth 5Y9.25%
Sales Q2Q%-12.55%

3.2 Future

Based on estimates for the next years, MRX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.14% on average per year.
MRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.67% yearly.
EPS Next Y52.67%
EPS Next 2Y31.09%
EPS Next 3Y22.14%
EPS Next 5YN/A
Revenue Next Year-12.04%
Revenue Next 2Y-4.76%
Revenue Next 3Y-1.73%
Revenue Next 5Y11.67%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MRX.DE Yearly Revenue VS EstimatesMRX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
MRX.DE Yearly EPS VS EstimatesMRX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRX.DE Price Earnings VS Forward Price EarningsMRX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRX.DE Per share dataMRX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

MRX's earnings are expected to grow with 22.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.09%
EPS Next 3Y22.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MISTER SPEX SE

FRA:MRX (9/5/2025, 7:00:00 PM)

1.69

-0.15 (-8.15%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)05-08 2024-05-08/amc
Earnings (Next)N/A N/A
Inst Owners24.87%
Inst Owner ChangeN/A
Ins Owners3.98%
Ins Owner ChangeN/A
Market Cap59.23M
Analysts77.5
Price Target4.42 (161.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.61%
PT rev (3m)4.65%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.27%
EPS NY rev (3m)6.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.28
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS6
BVpS1.87
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.1%
ROE -125.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.82%
FCFM N/A
ROA(3y)-27.31%
ROA(5y)-20%
ROE(3y)-57.09%
ROE(5y)-43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y0.94%
F-Score2
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.67%
Cap/Sales 2.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 1.82
Altman-Z -2.11
F-Score2
WACC5.14%
ROIC/WACCN/A
Cap/Depr(3y)41.44%
Cap/Depr(5y)71.03%
Cap/Sales(3y)6.28%
Cap/Sales(5y)7.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.59%
EPS Next Y52.67%
EPS Next 2Y31.09%
EPS Next 3Y22.14%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.33%
Revenue growth 3Y3.73%
Revenue growth 5Y9.25%
Sales Q2Q%-12.55%
Revenue Next Year-12.04%
Revenue Next 2Y-4.76%
Revenue Next 3Y-1.73%
Revenue Next 5Y11.67%
EBIT growth 1Y-66.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year96.97%
EBIT Next 3Y32.58%
EBIT Next 5Y29.96%
FCF growth 1Y60.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.14%
OCF growth 3YN/A
OCF growth 5YN/A